Overview

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

Status:
Completed
Trial end date:
2021-02-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab